Rapid diagnosis of acute promyelocytic leukemia by analyzing the immunocytochemical pattern of the PML protein with the monoclonal antibody PG-M3.

The fusion protein, promyelocytic leukemia-retinoic acid receptor (PML-RAR)alpha, generated by the t(15;17) translocation has an abnormal cellular distribution with colocalization of RARalpha and PML proteins. We analyzed the immunostaining pattern of PML protein using the PG-M3 monoclonal antibody directed against the amino terminal portion of PML (retained in wild-type PML and PML-RARalpha fusion protein) in the diagnosis of acute promyelocytic leukemia (APL). In addition, we compared this test with other methods for detecting the PML-RARalpha fusion gene. A normal immunostaining pattern was observed in nonmyeloid disorders and in 78 of 111 acute myeloid leukemias (AMLs). A microgranular pattern was observed in 25 AMLs, all corresponding to APL. These results were concordant with the reverse transcriptase-polymerase chain reaction results for PML-RARalpha fusion gene. Only 1 case positive for the PML-RARalpha transcript showed a normal protein pattern by immunocytochemistry. PML immunostaining was helpful to rapidly differentiate 7 cases with borderline characteristics and to obtain the diagnosis in 2 cases with scarce material. The effectiveness and low cost of this technique support its routine use as a first-line procedure in the differential diagnosis of AML.

[1]  C. Bloomfield,et al.  All-trans-Retinoic Acid in Acute Promyelocytic Leukemia , 2000 .

[2]  J. Esteve,et al.  A Modified AIDA Protocol With Anthracycline-Based Consolidation Results in High Antileukemic Efficacy and Reduced Toxicity in Newly Diagnosed PML/RAR-Positive Acute Promyelocytic Leukemia , 1999 .

[3]  J. Miguel,et al.  A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. , 1999, Blood.

[4]  B. Falini,et al.  Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. , 1999, Blood.

[5]  D. Grimwade,et al.  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Presenting White Blood Cell Count and Kinetics of Molecular Remission Predict Prognosis in Acute Promyelocytic Leukemia Treated With All- Trans Retinoic Acid: Result of the Randomized MRC Trial , 2022 .

[6]  B. Bain,et al.  Identification of the t(15;17) in AML FAB types other than M3: evaluation of the role of molecular screening for the PML/RARα rearrangement in newly diagnosed AML , 1999 .

[7]  B. Bain,et al.  Identification of the t(15;17) in AML FAB types other than M3: evaluation of the role of molecular screening for the PML/RARalpha rearrangement in newly diagnosed AML. The Medical Research Council (MRC) Adult Leukaemia Working Party. , 1999, British journal of haematology.

[8]  J. Hernández-Rivas,et al.  The flow cytometric pattern of CD34, CD15 and CD13 expression in acute myeloblastic leukemia is highly characteristic of the presence of PML-RARalpha gene rearrangements. , 1999, Haematologica.

[9]  J. Esteve,et al.  A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. , 1999, Blood.

[10]  F. Mandelli,et al.  Acute promyelocytic leukemia: a curable disease , 1998, Leukemia.

[11]  B. Leber,et al.  PML/RARα APL with undifferentiated morphology and stem cell immunophenotype , 1998, Leukemia.

[12]  F. Mandelli,et al.  Early Detection of Relapse by Prospective Reverse Transcriptase-Polymerase Chain Reaction Analysis of the PML/RARα Fusion Gene in Patients With Acute Promyelocytic Leukemia Enrolled in the GIMEMA-AIEOP Multicenter “AIDA” Trial , 1998 .

[13]  W. Miller,et al.  An immunofluorescent assay for acute promyelocytic leukemia cells. , 1998, American journal of clinical pathology.

[14]  F. Mandelli,et al.  Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. GIMEMA-AIEOP Multicenter "AIDA" Trial. , 1998, Blood.

[15]  B. Leber,et al.  PML/RAR alpha APL with undifferentiated morphology and stem cell immunophenotype. , 1998, Leukemia.

[16]  G. Morgan,et al.  The rapid diagnosis of acute promyelocytic leukaemia using PML (5E10) monoclonal antibody , 1997, British journal of haematology.

[17]  S. Pileri,et al.  Immunocytochemical diagnosis of acute promyelocytic leukemia (M3) with the monoclonal antibody PG-M3 (anti-PML). , 1997, Blood.

[18]  B. Leber,et al.  Morphology of acute promyelocytic leukemia with cytogenetic or molecular evidence for the diagnosis: Characterization of additional microgranular variants , 1997, American journal of hematology.

[19]  C. Bloomfield,et al.  All-trans-retinoic acid in acute promyelocytic leukemia. , 1997, The New England journal of medicine.

[20]  L. Maffei,et al.  A microgranular variant of acute promyelocytic leukemia with atypical morpho-cytochemical features and an early myeloid immunophenotype. , 1997, Leukemia research.

[21]  M. Chester,et al.  Variant complex translocations involving chromosomes 1, 9, 9, 15 and 17 in acute promyelocytic leukemia without RARα/PML gene fusion rearrangement , 1997, Leukemia.

[22]  W. Huang,et al.  A case of acute eosinophilic granulocytic leukemia with PML-RAR alpha fusion gene expression and response to all-trans retinoic acid , 1997, Leukemia.

[23]  C. Peschle,et al.  Effects on differentiation by the promyelocytic leukemia PML/RARalpha protein depend on the fusion of the PML protein dimerization and RARalpha DNA binding domains. , 1996, The EMBO journal.

[24]  D. Grimwade,et al.  Establishing the presence of the t( 15; 17) in suspected acute promyelocytic leukaemia: cytogenetic, molecular and PML immunofluorescence assessment of patients entered into the M.R.C. ATRA trial , 1996, British journal of haematology.

[25]  F. Mandelli,et al.  Improved rapid detection of the PML/RARalpha fusion gene in acute promyelocytic leukemia. , 1996, Leukemia.

[26]  F. Mitelman.  ISCN 1995 : an international system for human cytogenetic nomenclature (1995) : recommendations of the International Standing Committee on Human Cytogenetic Nomenclature : Memphis, Tennessee, USA, October 9-13, 1994 , 1995 .

[27]  G. Avvisati,et al.  Combined cytogenetic, FISH and molecular analysis in acute promyelocytic leukaemia at diagnosis and in complete remission , 1995, British journal of haematology.

[28]  S. Pileri,et al.  Characterization of a new monoclonal antibody (PG-M3) directed against the aminoterminal portion of the PML gene product: immunocytochemical evidence for high expression of PML proteins on activated macrophages, endothelial cells, and epithelia. , 1995, Blood.

[29]  F. Mancini,et al.  Acute myeloid leukemias M2 potentially misdiagnosed as M3 variant French-American-Britain (FAB) subtype: a transitional form? , 1995, Leukemia & lymphoma.

[30]  R. Warrell,et al.  Rapid diagnosis of acute promyelocytic leukemia by immunohistochemical localization of PML/RAR-alpha protein. , 1995, Blood.

[31]  M. Grever,et al.  HLA-DR-, CD33+, CD56+, CD16- myeloid/natural killer cell acute leukemia: a previously unrecognized form of acute leukemia potentially misdiagnosed as French-American-British acute myeloid leukemia-M3. , 1994, Blood.

[32]  N. Stuurman,et al.  The t(15;17) translocation alters a nuclear body in a retinoic acid‐reversible fashion. , 1994, The EMBO journal.

[33]  Maria Carmo-Fonseca,et al.  Retinoic acid regulates aberrant nuclear localization of PML-RARα in acute promyelocytic leukemia cells , 1994, Cell.

[34]  P. Mannucci,et al.  Acute promyelocytic leukemia with unusual morphological features, absence of the t(15,17) and rearranged PML/RAR alpha genes. , 1994, Haematologica.

[35]  J. Melo,et al.  An optimized multiplex polymerase chain reaction (PCR) for detection of BCR-ABL fusion mRNAs in haematological disorders. , 1994, Leukemia.

[36]  P. Pandolfi,et al.  Acute promyelocytic leukemia: from genetics to treatment. , 1994, Blood.

[37]  H. de Thé,et al.  PML protein expression in hematopoietic and acute promyelocytic leukemia cells. , 1993, Blood.

[38]  S. Waxman,et al.  Acute promyelocytic leukemia: clinical relevance of two major PML-RAR alpha isoforms and detection of minimal residual disease by retrotranscriptase/polymerase chain reaction to predict relapse. , 1993, Blood.

[39]  E. Solomon,et al.  Molecular analysis of the t(15;17) translocation in acute promyelocytic leukaemia. , 1992, Bailliere's clinical haematology.

[40]  P. Chambon,et al.  Structure, localization and transcriptional properties of two classes of retinoic acid receptor alpha fusion proteins in acute promyelocytic leukemia (APL): structural similarities with a new family of oncoproteins. , 1992, The EMBO journal.

[41]  H. Gralnick,et al.  Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML‐MO) , 1991, British journal of haematology.

[42]  E. Besa.  Acute promyelocytic leukemia. , 1991, Blood.

[43]  Zhen-yi Wang,et al.  Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. , 1988, Haematology and blood transfusion.

[44]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[45]  G Flandrin,et al.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.

[46]  Iscn.  International System for Human Cytogenetic Nomenclature , 1978 .